Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORCEPT-E 1/35 21 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin secretion, preventing ovulation; progestin (norethindrone) alters cervical mucus, endometrial lining, and inhibits sperm penetration.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Oral contraceptive
Prevention of pregnancy (FDA-approved)
One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no tablets. Repeat cycle continuously.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Ethinyl estradiol: terminal half-life approximately 17 hours (range 13-27 hours), consistent with once-daily dosing; norethindrone: terminal half-life approximately 7.6 hours (range 5-12 hours), permitting steady-state within 5 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: primarily metabolized by CYP3A4; norethindrone: primarily metabolized by CYP3A4 and reduction.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: 50-60% as metabolites (primarily ethinyl estradiol glucuronide and norethindrone metabolites); fecal: 20-30% via biliary elimination; unchanged drug: <5%.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 61-65% bound to albumin and SHBG.
~99% bound to serum albumin and sex hormone-binding globulin.
Ethinyl estradiol: 2.3-4.3 L/kg, indicating extensive tissue distribution; norethindrone: 3.4-4.2 L/kg, consistent with distribution beyond plasma volume.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: ethinyl estradiol 40-45% (first-pass metabolism); norethindrone 60-65% (first-pass metabolism).
Oral: ~70% due to first-pass metabolism.
No dosage adjustment required for mild to moderate renal impairment. Avoid use in severe renal impairment or end-stage renal disease due to potential fluid retention and hormonal metabolism alterations.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute or chronic hepatic impairment (Child-Pugh class A, B, or C) due to impaired steroid hormone clearance and increased risk of adverse effects.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. For adolescent females, same dosing as adults: one tablet daily for 21 days, then 7 days off. Weight-based adjustments not required; use standard dosing if post-menarche.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use after menopause. No specific dosing adjustments studied; avoid use in elderly due to increased risk of thromboembolic events and lack of benefit for postmenopausal contraception.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking intensity (especially in women over 35). Women should not smoke while using this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders,Cardiovascular disease risk,Carcinoma of breast and reproductive organs,Hepatic neoplasia,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid effects,Headache,Bleeding irregularities,Ectopic pregnancy,Depression
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebral vascular or coronary artery disease,Known or suspected breast cancer,Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Current or past history of ischemic heart disease,Diabetes with vascular involvement,Headaches with focal neurological symptoms,Major surgery with prolonged immobilization,Known hypercoagulopathies,Uncontrolled hypertension,Smoking in women over 35 years,Severe renal disease
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically significant. Maintain consistent dietary habits to avoid gastrointestinal upset.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Epidemiological studies have not revealed an increased risk of birth defects in infants born to women who used oral contraceptives (OCs) before pregnancy or inadvertently during early pregnancy. However, OCs are contraindicated during pregnancy due to potential hormonal effects on the developing fetus. Use of OCs during the second and third trimesters is not associated with teratogenicity, but has been linked to an increased risk of fetal outcomes such as low birth weight and possibly congenital anomalies in some studies, though not consistently. The overall risk is considered low, but OCs should be discontinued if pregnancy is confirmed.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of oral contraceptive steroids have been identified in breast milk, with an estimated infant dose of 0.1% to 1% of the maternal daily dose. The milk-to-plasma ratio (M/P) for ethinyl estradiol is approximately 0.42 under steady-state conditions. Use of combined oral contraceptives during lactation may reduce milk production and breast milk quality, especially when initiated soon after delivery. Therefore, use of combined OCs is generally not recommended during breastfeeding, particularly in the first 6 months postpartum. Progestin-only preparations are preferred.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Norcept-E 1/35 21 is contraindicated during pregnancy and should not be used. Therefore, no dosing adjustments are applicable; the drug should be discontinued immediately if pregnancy occurs. No pharmacokinetic studies have been conducted in pregnant women, but physiological changes (e.g., increased volume of distribution, increased renal clearance) would occur if taken, but no dose adjustment is recommended because use is contraindicated.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
This product contains norethindrone 1 mg and ethinyl estradiol 35 mcg. It is a monophasic oral contraceptive. Counsel patients to take at the same time daily. If a dose is missed, follow standard missed pill guidelines. Use additional non-hormonal contraception during first 7 days of initial cycle. Avoid use in smokers over 35 years of age due to increased thromboembolic risk. Monitor for signs of thrombosis, hypertension, and mood changes. May reduce milk supply in breastfeeding women.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time each day, even if you do not have sex.,If you miss a pill, refer to the patient leaflet or ask your healthcare provider for instructions.,Use a backup method (like condoms) for the first 7 days when starting the pill.,Do not smoke cigarettes while taking this medication, especially if you are over 35.,Seek medical help immediately if you experience severe leg pain, chest pain, shortness of breath, severe headache, or vision changes.,This medication does not protect against HIV or other sexually transmitted infections.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORCEPT-E 1/35 21 vs AFIRMELLE, answered by our medical review team.
NORCEPT-E 1/35 21 is a Combined Oral Contraceptive that works by Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin secretion, preventing ovulation; progestin (norethindrone) alters cervical mucus, endometrial lining, and inhibits sperm penetration.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORCEPT-E 1/35 21 and AFIRMELLE depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORCEPT-E 1/35 21 is: One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no tablets. Repeat cycle continuously.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORCEPT-E 1/35 21 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORCEPT-E 1/35 21 is classified as Category C. Epidemiological studies have not revealed an increased risk of birth defects in infants born to women who used oral contraceptives (OCs) before pregnancy or inadvertently during ea. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.